No Data
No Data
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to
Barclays Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $12
Barclays analyst Carter Gould maintains $Travere Therapeutic(TVTX.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 53.5% and
Travere Gains on Novartis Data for Filspari Rival, Calliditas Buyout
Press Release: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May
Travere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities Health Care
Express News | Travere Therapeutics Inc : BofA Global Research Cuts Price Objective to $19 From $21
No Data